Long-term results of aortic valve replacement with the St. Jude Toronto stentless porcine valve.

BACKGROUND Long-term survival and freedom from valve-related events of the St. Jude Toronto stentless porcine valve (SPV) are unknown. The aim of this study was to investigate late clinical outcomes after aortic valve replacement with the Toronto SPV. METHODS Between 1992 and 2000, 200 patients (131 males, 69 females) underwent aortic valve replacement with the Toronto SPV. Mean patient age at implantation was 64.6 +/- 10.9 years (range 33 to 82 years). At the time of operation, 32%, 51%, and 17% of patients were in New York Heart Association class I/II, III, and IV, respectively. Aortic stenosis, aortic insufficiency, and combined lesions were present in 64%, 13.5%, and 22.5% of patients preoperatively. Concomitant coronary artery bypass grafting was performed in 34.5% of patients. RESULTS Perioperative mortality occurred in 2.5% (5/200) of patients. There were 31 late deaths. Actuarial survival at 5 and 10 years was 89.2% and 68.0%, respectively. There was no significant difference in overall actuarial survival between isolated valve patients and valve plus coronary artery bypass grafting patients, 71% versus 62% respectively, p = 0.85. Actuarial freedom from valve reoperation at 5 and 10 years was 97.6% and 79.9%, respectively. Actuarial freedom from structural valve deterioration was 98.8% at 5 years and declined to 77.9% at 10 years. Freedom from structural valve deterioration was poorer in patients with preoperative aortic insufficiency or bicuspid disease. Actuarial freedom from embolic events and endocarditis at 10 years were 94.6% and 95.9%, respectively. CONCLUSIONS Although early clinical results were excellent, a significant increase in hazard for structural valve deterioration occurred in late follow-up.

[1]  N G Smedira,et al.  Long-term results of the Carpentier-Edwards pericardial aortic valve: a 12-year follow-up. , 1998, The Annals of thoracic surgery.

[2]  F. Schoen,et al.  Effects of fixation back pressure and antimineralization treatment on the morphology of porcine aortic bioprosthetic valves. , 1993, The Journal of thoracic and cardiovascular surgery.

[3]  S. Armstrong,et al.  Late results of heart valve replacement with the Hancock II bioprosthesis. , 2001, The Journal of thoracic and cardiovascular surgery.

[4]  K. Bielenberg,et al.  Ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve: involvement and clinical relevance of smooth muscle cell apoptosis and expression of cell death-initiating proteins. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  F. Santini,et al.  Hancock versus stentless bioprosthesis for aortic valve replacement in patients older than 75 years. , 1998, The Annals of thoracic surgery.

[6]  J. Pepper,et al.  Perioperative assessment of aortic homograft, Toronto stentless valve, and stented valve in the aortic position. , 1995, The Annals of thoracic surgery.

[7]  B S Goldman,et al.  Inaccurate and misleading valve sizing: a proposed standard for valve size nomenclature. , 1998, The Annals of thoracic surgery.

[8]  G. Berg,et al.  Randomized controlled trial of stented and stentless aortic bioprotheses: hemodynamic performance at 3 years. , 1999, Seminars in thoracic and cardiovascular surgery.

[9]  V. Rao,et al.  Are stentless valves hemodynamically superior to stented valves? A prospective randomized trial. , 2002, The Annals of thoracic surgery.

[10]  G. Deeb,et al.  Impact of implant technique following freestyle stentless aortic valve replacement. , 2002, The Annals of thoracic surgery.

[11]  M. Eriksson,et al.  Dilation of the sinotubular junction causes aortic insufficiency after aortic valve replacement with the Toronto SPV bioprosthesis. , 2001, The Journal of thoracic and cardiovascular surgery.

[12]  D. Tzivoni,et al.  Comparison of Exercise Hemodynamics Among Nonstented Aortic Bioprostheses, Mechanical Valves, and Normal Native Aortic Valves , 1998, Journal of cardiac surgery.

[13]  L. Cohn,et al.  Guidelines for reporting morbidity and mortality after cardiac valvular operations. , 1988, The Journal of thoracic and cardiovascular surgery.

[14]  M. Fishbein,et al.  Tissue characterization and calcification potential of commercial bioprosthetic heart valves. , 2001, The Annals of thoracic surgery.

[15]  S. Armstrong,et al.  The impact of age, coronary artery disease, and cardiac comorbidity on late survival after bioprosthetic aortic valve replacement. , 1999, The Journal of thoracic and cardiovascular surgery.

[16]  Susan Armstrong,et al.  Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. , 2002, The Journal of thoracic and cardiovascular surgery.

[17]  T. David,et al.  Aortic valve replacement with the Toronto SPV: long-term clinical and hemodynamic results. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  G. Thiene,et al.  Long-term durability of the Hancock II porcine bioprosthesis. , 2003, The Journal of thoracic and cardiovascular surgery.

[19]  T. David,et al.  Analysis of explants and causes of mortality during long-term follow-up of the Toronto stentless porcine valve. , 2001, Seminars in thoracic and cardiovascular surgery.

[20]  F. Mohr,et al.  Prospectively randomized evaluation of stentless versus conventional biological aortic valves: impact on early regression of left ventricular hypertrophy. , 1999, Circulation.

[21]  B. Strauss,et al.  Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. , 2003, The Journal of thoracic and cardiovascular surgery.

[22]  T. David,et al.  Aortic valve replacement with the Toronto SPV bioprosthesis. , 1992, The Journal of heart valve disease.

[23]  J. Butany,et al.  The Toronto SPV bioprosthesis: review of morphological findings in eight valves. , 1999, Seminars in thoracic and cardiovascular surgery.